FDA's Office of Generic Drugs approved CIS-US' abbreviated new drug application to market a generic agent for hepatobiliary imaging, the company said in a news release. "Our approval of the Kit for the Preparation of Technetium Tc-99 Mebrofenin is a gratifying start to the expansion of our existing molecular imaging agent product line," the company's CEO said.

Full Story:

Related Summaries